A5084847095- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Head and Neck Cancer Studies
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Monoclonal and Polyclonal Antibodies Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Venous Thromboembolism Diagnosis and Management
- Helicobacter pylori-related gastroenterology studies
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Peptidase Inhibition and Analysis
Seoul National University Bundang Hospital
2016-2025
Seoul National University
2014-2025
New Generation University College
2010-2024
National University College
2010-2024
Centre Léon Bérard
2022
Université Claude Bernard Lyon 1
2022
Shizuoka Cancer Center
2018
Kindai University
2018
National Yang Ming Chiao Tung University
2018
National Cheng Kung University Hospital
2018
<h3>Importance</h3> Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. <h3>Objective</h3> To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with G/GEJ programmed cell death ligand 1 (PD-L1) combined positive score (CPS) greater. <h3>Design, Setting, Participants</h3> The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional...
Abstract Purpose: The Cancer Genome Atlas (TCGA) project recently uncovered four molecular subtypes of gastric cancer: Epstein–Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal (CIN). However, their clinical significances are currently unknown. We aimed to investigate the relationship between prognosis patients with cancer. Experimental Design: Gene expression data from a TCGA cohort (n = 262) were used develop subtype prediction model, association...
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared efficacy olaparib plus paclitaxel (olaparib/paclitaxel) alone in patients recurrent or metastatic gastric and assessed whether ATM expression is predictive improved clinical outcome for olaparib/paclitaxel. Patients Methods In this phase II, double-blind study (Study...
Nivolumab showed improvement in overall survival (OS) ATTRACTION-2, the first phase 3 study patients with gastric/gastroesophageal junction (G/GEJ) cancer treated ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.ATTRACTION-2 was a randomized, double-blind, placebo-controlled, trial (49 sites; Japan, South Korea, and Taiwan). median (min-max) period 27.3 (24.1-36.3) months. primary endpoint OS. A subanalysis OS performed based on best response...
To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.Patients with locally advanced metastatic HER2-low (cohort 1, immunohistochemistry 2+/in situ hybridization-negative; cohort 2, 1+) gastric/GEJ adenocarcinoma treated at least two prior regimens, including fluoropyrimidine platinum, but anti-HER2 therapy naive, received T-DXd 6.4 mg/kg intravenously once every 3...
To evaluate the efficacy and safety of tucatinib trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC).
Abstract Background We report the final results of randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 membranous staining by immunohistochemistry), HER-2–negative gastric or gastroesophageal junction cancer (GC). Methods Patients received bemarituzumab (15 mg/kg) placebo once every weeks an additional (7.5 dose on cycle 1 day 8. All...
Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed many cancers, including colorectal cancer. We investigated whether activation YAP1 is significantly associated with prognosis or treatment outcomes cancer.A gene expression signature reflecting was identified cancer cells, and patients were stratified into two groups according to this signature: activated (AYCC) inactivated (IYCC). Stratified five test cohorts evaluated determine effect on response cetuximab...
PURPOSE We evaluated the role of oxaliplatin as adjuvant chemotherapy in patients with rectal cancer who received preoperative chemoradiotherapy (CRT) fluoropyrimidine monotherapy and total mesorectal excision (TME). METHODS The ADORE trial (adjuvant cancer) is a multicenter, randomized postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) after fluoropyrimidine-based CRT TME. Patients were randomly assigned (1:1) to receive either FL (fluorouracil 380 mg/m 2 leucovorin 20 ) FOLFOX...
Loss of PTEN, the major negative regulator PI3K/AKT pathway induces a cellular senescence as failsafe mechanism to defend against tumorigenesis, which is called PTEN-loss-induced (PICS). Although many studies have indicated that mTOR plays critical role in senescence, exact functions mTORC1 and mTORC2 PICS are not well understood. In this study, we show acts relay molecule downstream upstream p53 PICS. We found PTEN depletion via p53-p21 signaling without triggering DNA damage response....
We evaluated the association between a KRAS mutational status and various clinicopathologic features including metastatic pattern in patients with or recurrent colorectal cancer (MRCRC). The concordance rates of primary tumor sites paired organs were also analyzed.The codons 12, 13, 61 from formalin-fixed sections both tumors related metastases was determined by sequencing analysis. One hundred forty-three Korean MRCRC available tissues (resection biopsy) consecutively enrolled.The mutation...
Immunotherapy has emerged as a promising anti-cancer treatment, however, little is known about the genetic characteristics that dictate response to immunotherapy. We develop transcriptional predictor of immunotherapy and assess its prediction in genomic data from ~10,000 human tissues across 30 different cancer types estimate potential The integrative analysis reveals two distinct tumor types: mutator type positively associated with immunotherapy, whereas chromosome-instable negatively it....
This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer gastroesophageal junction (GEJ) cancer. Second-line patients were randomized 2:2:1 to receive plus (arm A), B) C), third-line received D). A tumor-based IFNγ gene signature was prospectively evaluated a potential predictive biomarker second- receiving the E). The coprimary endpoints objective response rate...
To develop and compare delta-radiomics signatures from 2- (2D) 3-dimensional (3D) features that predict treatment outcomes following preoperative chemoradiotherapy (CCRT) surgery for locally advanced rectal cancer.In total, 101 patients (training cohort, n = 67; validation 34) with adenocarcinoma between 2008 2015 were included. We extracted 55 T2-weighted magnetic resonance imaging (MRI) scans. Delta-radiomics feature was defined as the difference in radiomics before after CCRT. Signatures...
2 Background: Recent clinical trials have established 1 st and nd line chemotherapy as the standard treatment for advanced gastric or gastro-esophageal junction cancer (AGC). However, prognosis of AGC is still poor. Nivolumab (ONO-4538/BMS-936558) a human monoclonal IgG4 antibody which blocks programmed cell death-1 (PD-1) receptor. We evaluated efficacy safety nivolumab salvage after failure AGC. Methods: 493 patients aged ≥ 20 years with ECOG PS 0-1 unresectable recurrent who had failed...